research A Prospective Observational Study for Assessment of Chemotherapy-Induced Adverse Drug Reactions in Cancer Patients
Females had more chemotherapy side effects than males, with many being preventable.
Search
for
Sort by
Research
300-330 / 1000+ resultsresearch Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Current Aspects of Antiandrogen Therapy in Women
Antiandrogen therapy is effective and well tolerated for treating women's androgenic disorders like hirsutism, acne, and hair loss.
research 32571 Intensive dutasteride mesotherapy protocol (IDMP) with oral minoxidil as an alternative to antiandrogens in AGA. A retrospective analysis of a hair restoration center
Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Behandlung mit Antiandrogenen in der Gynäkologie
Antiandrogen treatments can help with various women's health issues but often require ongoing use.
research News & Notes
Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
research 7472 Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients
Estrogen alone can lower testosterone in some transfeminine people.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N. Bennani and I. M. Bennani-Baiti
Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.
research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
research Study Answers Some Questions about Androgen Suppression Pre-Radiation, but Not All
Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
research ESTUDO DE CASO: MICROAGULHAMENTO E INTRADERMOTERAPIA COMO TRATAMENTOS NA ALOPÉCIA ANDROGENÉTICA EM MULHERES MENOPAUSADAS
Microagulhamento e intradermoterapia juntos melhoram o crescimento capilar em mulheres menopausadas.
research Cardiovascular effects of hormone therapy for prostate cancer
Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
research Iatrogenic androgen and estrogen excess in a postmenopausal woman presenting with facial erythema, acne, and hirsutism
A postmenopausal woman's facial redness, acne, and excess hair were caused by too much hormone therapy for insomnia, but improved after stopping the treatment.
research Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)
Testosterone patches can modestly improve sexual function in postmenopausal women not on estrogen therapy.
research Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
research Prevention and treatment of experimental prostate cancer in lobund-wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration
Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
research Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
research The use of testosterone after menopause
Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Tamoxifen-induced androgenetic alopecia in a dialysis patient with sclerosing encapsulating peritonitis (SEP)
research Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
research 7472 Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients
Estrogen alone may effectively suppress testosterone in some transfeminine individuals.